drugset / Trial / NCT04251585
Intranasal Insulin in Parkinson's Disease
RandomizedParallel-groupQuadruple-blindOther
Summary
This project will investigate exploratory outcomes related to the effect of intranasal insulin on cognition, mood, apathy and motor performance of subjects with Parkinson's disease over a 3 week period.
Timeline
- Start
- 2020-02-04
- Primary completion
- 2024-08-27
- Completion
- 2024-08-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Insulin | Protein / enzyme biologic | 20 iu | Intranasal |
| Subject | Insulin | Protein / enzyme biologic | 40 iu | Intranasal |
| Subject | Insulin | Protein / enzyme biologic | 80 iu | Intranasal |